{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:29:33Z","timestamp":1791167373314,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,12,1]]},"abstract":"<jats:p>PURPOSE: To evaluate preoperative dendritic cell (DC) mobilization and tumor infiltration after administration of Flt3 ligand (Flt3L) to patients with metastatic colon cancer.<\/jats:p><jats:p>PATIENTS AND METHODS: Twelve patients with colon cancer metastatic to the liver or lung received Flt3L (20 \u03bcg\/kg\/d subcutaneously for 14 days for one to three cycles at monthly intervals) before attempted metastasectomy. The number and phenotype of DCs mobilized into peripheral-blood mononuclear cells (PBMCs) were evaluated by flow cytometry. After surgical resection, metastatic tumor tissue was evaluated for DC infiltration. In vivo immune responses to recall antigens were measured.<\/jats:p><jats:p>RESULTS: After Flt3L administration, on average, the total number of leukocytes in the peripheral blood increased from 5.9 \u00b1 1.0 \u00d7 10<jats:sup>3<\/jats:sup>\/mm<jats:sup>3<\/jats:sup>to 11.2 \u00b1 3.8 \u00d7 10<jats:sup>3<\/jats:sup>\/mm<jats:sup>3<\/jats:sup>(mean \u00b1 SD, P = .0001). The percentage of CD11c<jats:sup>+<\/jats:sup>CD14<jats:sup>\u2212<\/jats:sup>DCs in PBMCs increased from 2.4% \u00b1 1.8% to 8.8% \u00b1 4.7% (P = .004). Delayed-type hypersensitivity (DTH) responses to recall antigens (Candida, mumps, and tetanus) showed marginally significant increases in reactivity after Flt3L administration (P = .06, P = .03, and P = .08, respectively). An increase in the number of DCs was observed at the periphery of the tumors of patients who received Flt3L compared with those of patients who had not.<\/jats:p><jats:p>CONCLUSION: Flt3L is capable of mobilizing DCs into the peripheral blood of patients with metastatic colon cancer and may be associated with increases in DC infiltration in the peritumoral regions. Flt3L mobilization is associated with a trend toward increased DTH responses to recall antigens in vivo. The use of Flt3L to increase circulating DCs for cancer immunotherapy should be considered.<\/jats:p>","DOI":"10.1200\/jco.2000.18.23.3883","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:57:30Z","timestamp":1487919450000},"page":"3883-3893","source":"Crossref","is-referenced-by-count":108,"title":["Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer"],"prefix":"10.1200","volume":"18","author":[{"given":"Michael A.","family":"Morse","sequence":"first","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Nair","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Fernandez-Casal","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Deng","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"St Peter","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Williams","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hobeika","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mosca","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Clay","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Ian","family":"Cumming","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clavien","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Proia","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Niedzwiecki","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Caron","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kim","family":"Lyerly","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC, and Immunex, Corporation, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0553","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0218-x"},{"key":"R2-0553","unstructured":"Broxmeyer HE, Lu L, Cooper S, et al: Flt3 ligand stimulates\/costimulates the growth of myeloid stem\/progenitor cells. Exp Hematol 23: 1121,1995-1129,"},{"key":"R3-0553","unstructured":"Chen K, Braun S, Lyman S, et al: Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57: 3511,1997-3516,"},{"key":"R4-0553","unstructured":"Esche C, Subbotin VM, Maliszewski C, et al: Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58: 380,1998-383,"},{"key":"R5-0553","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-625"},{"key":"R6-0553","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v18.i1-2.110"},{"key":"R7-0553","doi-asserted-by":"crossref","unstructured":"Peron JM, Esche C, Subbotin VM, et al: Flt3-ligand administration inhibits liver metastases: Role of NK cells. J Immunol 161: 6164,1998-6170,","DOI":"10.4049\/jimmunol.161.11.6164"},{"key":"R8-0553","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.5.1953"},{"key":"R9-0553","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1997.1152"},{"key":"R10-0553","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050576"},{"key":"R11-0553","doi-asserted-by":"crossref","unstructured":"Shaw SG, Maung AA, Steptoe RJ, et al: Expansion of functional NK cells in multiple tissue compartments of mice treated with flt3-ligand: Implications for anti-cancer and anti-viral therapy. J Immunol 161: 2817,1998-2824,","DOI":"10.4049\/jimmunol.161.6.2817"},{"key":"R12-0553","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950017130"},{"key":"R13-0553","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.11.2075"},{"key":"R14-0553","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.3.1036"},{"key":"R15-0553","unstructured":"Lebsack ME, McKenna JA, Hoek R, et al: Safety of Flt3 ligand in healthy volunteers. Blood 90: 170a,1997 (suppl 1, abstr 751)"},{"key":"R16-0553","unstructured":"Marakovsky E, Roux E, Teepe M, et al: Flt3 ligand increases peripheral blood dendritic cells in healthy volunteers. Blood 90: 581a,1997 (suppl 1, abstr)"},{"key":"R17-0553","unstructured":"Pulendran B, Burkeholder S, Kraus E, et al: Differential mobilization of distinct DC subsets in vivo by Flt3-ligand and G-CSF. Blood 94: 213a,1999 (suppl 1, abstr)"},{"key":"R18-0553","unstructured":"Fay J, Palucka K, Pulendran B, et al: In vivo mobilization of dendritic cell precursors in normal volunteers after FLT3-L administration. Blood 94: 379a,1999 (suppl 1, abstr)"},{"key":"R19-0553","unstructured":"Gasparetto C, Rooney B, Gasparetto M, et al: Mobilization of dendritic cells from patients with breast cancer using Flt3-ligand and G-CSF or GM-CSF. Blood 94: 636a,1999 (suppl 1, abstr)"},{"key":"R20-0553","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830270326"},{"key":"R21-0553","doi-asserted-by":"crossref","unstructured":"Ohm JE, Shurin MR, Esche C, et al: Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 163: 3260,1999-3268,","DOI":"10.4049\/jimmunol.163.6.3260"},{"key":"R22-0553","doi-asserted-by":"publisher","DOI":"10.3109\/00313029309090853"},{"key":"R23-0553","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.10.1417"},{"key":"R24-0553","doi-asserted-by":"crossref","unstructured":"Borges L, Miller RE, Jones J, et al: Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol 163: 1289,1999-1297,","DOI":"10.4049\/jimmunol.163.3.1289"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.23.3883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:24:36Z","timestamp":1692699876000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.23.3883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,1]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2000,12,1]]}},"alternative-id":["10.1200\/JCO.2000.18.23.3883"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.23.3883","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12,1]]}}}